Medicines - HCP - Article
Aimovig erenumab logo
Neuroscience
AIMOVIG® (erenumab)
Cosentyx secukinumab logo
Dermatology
Cosentyx® (secukinumab)
Cosentyx secukinumab logo
Rheumatology
Cosentyx® (secukinumab)
Fabhalta iptacopan logo
Haematology
FABHALTA®▼ (iptacopan)
Kesimpta ofatumumab logo
Neuroscience
KESIMPTA®▼ (ofatumumab)
Kisqali ribociclib logo
Oncology
KISQALI® (ribociclib)
Leqvio inclisiran logo
Cardio-metabolic
LEQVIO®▼ (inclisiran)
Lutathera logo
 
LUTATHERA® (lutetium [177Lu] oxodotreotide)
Pluvicto logo
 
Pluvicto®▼ (lutetium [177Lu] vipivotide tetraxetan)
SCEMBLIX®▼ (asciminib) logo
Haematology
SCEMBLIX®▼ (asciminib)
SANDOSTATIN® LAR® (octreotide acetate) logo
Oncology
SANDOSTATIN® LAR® (octreotide acetate)

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.


Source URL: https://www.pro.novartis.com/uk-en/medicines